Author(s): Mark A.F. Kendall
Millions of people die each year from infectious disease, and many more are affected by
A major stumbling block to the full use of improved immunotherapies (e.g.
against these problems is our limited ability to deliver genes and drugs to the required sites in
Specifically, effective methods to deliver genes and drugs into outer skin and mucosal
layers (sites with immunological, physical and practical advantages that cannot be targeted via
traditional delivery methods) are lacking.
This chapter investigates this particular challenge for
physical delivery approaches.
The skin structural and immunogenic properties are examined in
the context of the physical cell targeting requirements of the viable epidermis.
physical cell targeting technologies engineered to meet these needs are examined: needle and
syringe; diffusion patches; liquid jet injectors; microneedle arrays/patches; and biolistic particle
The focus then moves to biolistic particle delivery: we first analyse engineering these
systems to meet demanding clinical needs.
The interaction of biolistic devices with the skin
is also examined, focusing on the mechanical interactions of ballistic impact and cell death.
Finally, the current clinical outcomes of one key application of engineered delivery devices –
DNA vaccines – are discussed.
Size: 2,408 kb
Paper DOI: 10.2495/978-1-84564-096-5/10
the Full Article
You can purchase the full text version of this article in Adobe PDF format for the above price. Please click the 'Buy Paper' icon below to purchase this paper.
this page to a colleague.